About this trial
The goal of this study is to evaluate the feasibility of using information from wearable devices and self-reported symptoms to remotely monitor patients during immunotherapy. The main questions it aims to answer are:
* Is the digital remote patient monitoring tool feasible and acceptable to patients? * Do the alerts and guidance improve symptom management, quality of life, and engagement with the care team during treatment?
Participants will:
* Complete a demographic questionnaire at the beginning of the study and quality-of-life and health questionnaires at the beginning, midpoint, and end of study. * As feasible: At the beginning and end of the study, complete an in-person physical function assessment measuring balance (Short Physical Performance Battery).
If participant is randomly assigned to the intervention group, they will also:
* Complete weekly symptom ratings via digital remote patient monitoring tool * Wear a Fitbit activity tracker for 90 days. * At the end of the study, complete a semi-structured interview to provide feedback on the study.
Eligibility criteria
Qualifiers
within three months of starting immune checkpoint inhibitor therapy at UPMC Hillman Cancer Center for advanced melanoma;
age 18 years or older;
ability to read and write in English;
owns and uses a smartphone capable of running study applications
Disqualifiers
under 18 years old; and
unable to read and write in English
Trial design
Treatments tested in this trial
- Digital remote monitoring intervention
- Usual Care
Treatment groups
Locations
1Sponsors and collaborators
University of Pittsburgh
Lead sponsor